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AOM

:   azoxymethane

CCD

:   charge‐coupled device

DSS

:   dextran sodium sulfate

HO‐1

:   heme oxygenase‐1

ICG

:   indocyanine green

iNOS

:   inducible nitric oxide synthase

LPS

:   lipopolysaccharide

NTCP

:   sodium‐taurocholate co‐transporting polypeptide

PGE~2~

:   prostaglandin E~2~

TL488

:   *Lycopersicon esculentum* (tomato) lectin conjugated with DyLight 488

1. INTRODUCTION {#cas13564-sec-0001}
===============

Inflammatory bowel disease, such as Crohn\'s disease or ulcerative colitis, is a risk factor for the development of colitis‐associated colorectal cancer.[1](#cas13564-bib-0001){ref-type="ref"}, [2](#cas13564-bib-0002){ref-type="ref"}, [3](#cas13564-bib-0003){ref-type="ref"} It is difficult to detect colitis‐associated colorectal cancer using white‐light colonoscopy because of the background mucosal changes associated with long‐term colitis and morphological diversity of the cancer.[4](#cas13564-bib-0004){ref-type="ref"} Therefore, for screening colonoscopy to detect dysplasia or early stage cancer, four random biopsies every 10 cm of the whole colorectal tissue using white‐light endoscopy has traditionally been recommended.[4](#cas13564-bib-0004){ref-type="ref"} However, this approach is quite cumbersome and time consuming. Therefore, the development of detection techniques that provide biological information with sufficient sensitivity and specificity is necessary to improve the current situation.

Fluorescence tumor imaging using exogenous fluorescent tumor‐targeting agents has been investigated for applications in endoscopy.[5](#cas13564-bib-0005){ref-type="ref"}, [6](#cas13564-bib-0006){ref-type="ref"}, [7](#cas13564-bib-0007){ref-type="ref"} In this technique, neoplastic lesions are visually enhanced with specific biomarkers targeted by the fluorescent agents. The advantages of fluorescence tumor imaging include its high specificity and sensitivity, real‐time video frame‐rate imaging, relatively low cost, portability, and the absence of radiation exposure.[8](#cas13564-bib-0008){ref-type="ref"}, [9](#cas13564-bib-0009){ref-type="ref"} It may, therefore, be a valuable method in early cancer detection. However, despite the variety of tumor imaging agents developed thus far, many of those intended for use in humans are still in preclinical or early phase clinical trials.[6](#cas13564-bib-0006){ref-type="ref"}

Indocyanine green is a fluorescent contrast agent approved for clinical applications in the USA and some European and Asian countries, including Japan. Because i.v. administered ICG is excreted exclusively by the liver, it has been used for decades to assess hepatic function in humans and has an excellent safety profile.[10](#cas13564-bib-0010){ref-type="ref"} Recently, tumor accumulation of ICG has been reported in a variety of tumor types, including tumors of the liver,[11](#cas13564-bib-0011){ref-type="ref"}, [12](#cas13564-bib-0012){ref-type="ref"} breast,[13](#cas13564-bib-0013){ref-type="ref"} head and neck,[14](#cas13564-bib-0014){ref-type="ref"} and lungs[15](#cas13564-bib-0015){ref-type="ref"} in humans. Detection of tumor metastatic lesions using ICG has also been reported in ovaries[16](#cas13564-bib-0016){ref-type="ref"} and colon.[17](#cas13564-bib-0017){ref-type="ref"}, [18](#cas13564-bib-0018){ref-type="ref"}, [19](#cas13564-bib-0019){ref-type="ref"}, [20](#cas13564-bib-0020){ref-type="ref"} However, the mechanism allowing tumor detection by ICG is poorly understood.

Currently, there are three potential mechanisms of ICG‐based tumor imaging. In hepatic tumors, ICG positivity is partly correlated with influx transporters, organic anion transporting polypeptide 1B3 and NTCP,[21](#cas13564-bib-0021){ref-type="ref"}, [22](#cas13564-bib-0022){ref-type="ref"} both of which are normally expressed in hepatocytes and mediate the cellular uptake of ICG in vitro.[23](#cas13564-bib-0023){ref-type="ref"} In experimental tumor models of the colon, endocytosis associated with tight junction disruption of the epithelial cells has been shown to increase ICG uptake capability.[24](#cas13564-bib-0024){ref-type="ref"}, [25](#cas13564-bib-0025){ref-type="ref"} In other cases, ICG‐based tumor imaging is thought to be caused by the enhanced permeability and retention effect of the nano‐sized ICG--plasma protein complex.[26](#cas13564-bib-0026){ref-type="ref"} Indocyanine green fluorescence signal intensity in the tumor tissues correlates with microvascular density,[27](#cas13564-bib-0027){ref-type="ref"} which is one of the parameters affecting the enhanced permeability and retention effect. Revealing the tumor imaging mechanism of ICG supports the precise clinical usage of ICG in tumor detection.

The aim of this study is to investigate the tumor imaging capability and the imaging mechanism of i.v. administered ICG in a mouse model of colitis‐associated colon cancer. To do this, we examined the imaging capability of ICG using ex vivo wide‐field imaging in an AOM/DSS‐induced colon carcinogenesis model. We further investigated the mechanism underlying tumor tissue uptake of ICG using ex vivo microscopic imaging, immunofluorescence analysis, and cultured cell experiments.

2. MATERIALS AND METHODS {#cas13564-sec-0002}
========================

2.1. Fluorescent agents {#cas13564-sec-0003}
-----------------------

Pharmaceutical grade ICG was purchased from Daiichi‐Sankyo (Diagnogreen; Tokyo, Japan). Blood vessels were visualized using TL488 (Vector Laboratories, Burlingame, CA, USA).

2.2. Fluorescence imaging systems {#cas13564-sec-0004}
---------------------------------

The basic specifications of fluorescence imaging systems has been reported previously.[24](#cas13564-bib-0024){ref-type="ref"} Briefly, macroscopic images were captured using a fluorescence reflectance imaging system (OV100; Olympus, Tokyo, Japan) equipped with a 150 W xenon light source and a color digital CCD camera (DP71; Olympus). Excitation and emission filters for ICG fluorescence imaging were 730 ± 22.5‐nm band‐pass and 770‐nm long‐pass filter, respectively. High‐power view was observed using a multi‐wavelength laser scanning microscope (IV100; Olympus) equipped with a 748‐nm diode laser with 17 mW power output and a photomultiplier tube. The emission filter to detect ICG fluorescence was a 779‐nm long‐pass filter. Tissue sections were scanned using a fluorescence virtual microscopy system (VS120‐FL; Olympus) equipped with a 200 W mercury light source (X‐Cite exacte; Excelitas Technologies, Waltham, MA, USA) and a monochrome digital CCD camera (ORCA‐R2; Hamamatsu Photonics, Hamamatsu, Japan). Excitation and emission filters for ICG fluorescence were 708 ± 37.5‐nm band‐pass and 809 ± 40.5‐nm band‐pass filter, respectively. Fluorescence images are shown in grayscale or pseudo‐colors.

2.3. Experimental tumor model {#cas13564-sec-0005}
-----------------------------

The AOM/DSS‐induced colitis‐associated colon cancer mouse model was constructed according to the methods described previously,[28](#cas13564-bib-0028){ref-type="ref"}, [29](#cas13564-bib-0029){ref-type="ref"}, [30](#cas13564-bib-0030){ref-type="ref"} with some modifications. The 38 female ICR mice (4 weeks old) used in this study were purchased from Japan SLC (Shizuoka, Tokyo). They were fed MF (Oriental Yeast, Tokyo, Japan) as a basal diet and provided with water ad libitum throughout the experimental period. Starting at 5 weeks of age, the mice received a single i.p. injection of AOM (10 mg/kg body weight; Sigma‐Aldrich, St. Louis, MO, USA). One week after the AOM injections, recurrent colitis was induced by administration of 5 w/v% DSS (MP Biochemicals, Santa Ana, CA, USA) in drinking water for 1 week. The mice that showed severe weight loss or serious hematochezia during the 1 week of DSS treatment had their DSS discontinued immediately. For in vivo vascular permeability assay, four female BALB/c nude mice (7 weeks old) were purchased from Japan SLC. They received CA‐1 (Nihon CLEA, Tokyo, Japan) as a basal diet and tap water ad libitum throughout the experimental period. All animal experiments were undertaken in accordance with the guidelines for animal experimentation of the Facility of Agriculture, Tokyo University of Agriculture and Technology (Tokyo, Japan).

2.4. Ex vivo imaging {#cas13564-sec-0006}
--------------------

Imaging experiments were carried out 4‐6, 10‐12, and 18‐20 weeks after injection of AOM (n = 10‐11 for each time period). The AOM/DSS‐treated mice (n = 5 for 4‐6 weeks*,* n = 6 for 10‐12 weeks, and n = 9 for 18‐20 weeks) were i.v. injected with 100 μL (7.5 mg/kg) ICG[24](#cas13564-bib-0024){ref-type="ref"} and left untreated for 1 hour. The blood circulation time of ICG was determined based on the results of preliminary experiments of ex vivo colon tumor imaging at different exposure time points (n = 1 each for 30 minutes and 6 hours at the time period of 4‐6 weeks; Figure [S1](#cas13564-sup-0001){ref-type="supplementary-material"}). The AOM/DSS‐treated mice without ICG injection were also prepared (n = 3 for 4‐6 weeks and 10‐12 weeks, and n = 1 for 18‐20 weeks). The AOM/DSS‐untreated control mice were injected with ICG (n = 3 for 4‐6 and n = 3 for 18‐20 weeks). In these animals, TL488 was i.v. injected at 100 μg/100 μL per mouse 10 minutes before they were killed by exsanguination under isoflurane anesthesia. The excised colon tissues were cut to reveal the intestinal mucosa, washed with PBS (pH 7.4), and then subjected to ex vivo imaging. As a control, colon tissues from AOM/DSS‐treated mice without ICG administration or normal mice with ICG administration were used. A preliminary experiment with an ICG enema was also undertaken, as previously reported.[25](#cas13564-bib-0025){ref-type="ref"} The AOM/DSS‐treated mice (n = 1 each for 4‐6 and 10‐12 weeks) were given 500 μL ICG at 30 μg/mL by enema and then subjected to imaging analysis as described above.

2.5. Histology and immunofluorescence {#cas13564-sec-0007}
-------------------------------------

In all animals, the excised colon tissues used in the histopathological examination were fixed overnight in phosphate‐buffered 10% formalin (pH 7.4). Paraffin‐embedded tissue sections stained with H&E were used to diagnose the proliferative lesions in the mouse colon. The proliferative lesions were histopathologically classified as dysplasia, adenoma, and adenocarcinoma.[30](#cas13564-bib-0030){ref-type="ref"}, [31](#cas13564-bib-0031){ref-type="ref"} Immunofluorescence was carried out using methanol‐fixed snap‐frozen sections of colon tissues obtained from the mice 18‐20 weeks after their i.p. injection of AOM. The sections were incubated with primary antibodies (Table [S1](#cas13564-sup-0001){ref-type="supplementary-material"}) overnight at 4°C, and then with species‐appropriate antibodies labeled with Alexa Fluor 488 or 594 (Thermo Fisher Scientific, Waltham, MA, USA) for 1 hour at room temperature, and counterstained with DAPI (Thermo Fisher Scientific).

2.6. In vivo vascular permeability assay {#cas13564-sec-0008}
----------------------------------------

In vivo vascular permeability was measured as reported previously,[32](#cas13564-bib-0032){ref-type="ref"} with some modifications. Prostaglandin E~2~ (2 μg/20 μL/ear) was intradermally injected to the right ear of the normal nude mice (n = 4). As a control, the same amount of PBS was injected to the left ear. Fifteen minutes after PGE~2~ injection, ICG (7.5 mg/kg body weight) was given i.v. One minute after ICG injection, macroscopic imaging using OV100 was carried out to detect vascularity of the ears. Approximately 10‐12 min after ICG injection, ICG accumulation in the ear was observed by IV100. Fluorescence signals were measured using OV100 or IV100 software.

2.7. Statistical analysis {#cas13564-sec-0009}
-------------------------

Fluorescence images were analyzed using ImageJ software (NIH, Bethesda, MD, USA). The mean fluorescence intensity of ICG in colon tissues was measured and then the tumor to normal tissue ratio was calculated. Numerical data are presented as the mean ± SD. Numerical data of the in vivo study, consisting of more than three sample groups, were assessed using Tukey--Kramer\'s test after verification of homogeneity of the variances by Bartlett\'s test. The Steel--Dwass test was applied for heterogeneous data. Numerical data of the in vitro study, consisting of four sample groups, were analyzed using Bartlett\'s test for homogeneity of variance. If the variance was homogenous, numerical data were assessed using Dunnett\'s test. For heterogeneous data, Steel\'s test was applied. The matched‐pair *t*‐test was applied to compare ICG fluorescence signal difference between the PGE~2~ injection side and PBS injection side.

3. RESULTS {#cas13564-sec-0010}
==========

3.1. Colon tumor detection capability of i.v. ICG in a mouse model of colitis‐associated colon cancer {#cas13564-sec-0011}
-----------------------------------------------------------------------------------------------------

No colonic proliferative lesions were observed in two mice of the 10‐12‐observation week group, and one in the 18‐20‐observation week group in AOM/DSS‐treated mice. All of the remaining AOM/DSS‐treated mice revealed multiple proliferative lesions of various sizes in the perianal area. Ex vivo wide‐field imaging revealed strong ICG fluorescence in proliferative lesions in each time period (Figure [1](#cas13564-fig-0001){ref-type="fig"}A, Figure [S1](#cas13564-sup-0001){ref-type="supplementary-material"}), whereas autofluorescence was rarely observed in ICG non‐administered AOM/DSS‐treated mice (Figure [1](#cas13564-fig-0001){ref-type="fig"}A, Figure [S1](#cas13564-sup-0001){ref-type="supplementary-material"}). In the untreated control mice injected with ICG, slight ICG fluorescence was only observed at the perianal area, reflecting the thickness of the perianal tissues. Lymphoid follicles in the colon tissues also showed moderate ICG fluorescence in ICG‐administered mice (Figure [1](#cas13564-fig-0001){ref-type="fig"}A). Indocyanine green fluorescence signal in the proliferative lesions in AOM/DSS‐treated mice was significantly higher than that of colon tissues in normal mice or non‐tumor tissues in AOM/DSS‐treated mice (Figure [1](#cas13564-fig-0001){ref-type="fig"}B, Figure [S1](#cas13564-sup-0001){ref-type="supplementary-material"}). In AOM/DSS‐treated mice, the tumor to normal tissue ratio was \>2 and significantly higher than that of the ICG non‐administered group in each time period (Figure [1](#cas13564-fig-0001){ref-type="fig"}C).

![Ex vivo imaging of mouse colon tumor tissues after i.v. administration of indocyanine green (ICG). Colon tissues of azoxymethane (AOM)/dextran sodium sulfate (DSS)‐treated mice with/without ICG injection or untreated mice with ICG injection were subjected to observation 1 h after i.v. administration of ICG at 4‐6, 10‐12, and 18‐20 weeks after AOM initiation. (A) White light (WL) images or fluorescence (FL) images (magenta) in each time period. Arrows and arrowheads indicate tumor tissues and lymphoid follicles, respectively. (B) Mean fluorescence intensity (MFI) of ICG in colon tissues in the time period of 18‐20 weeks after AOM initiation. Treatment groups: n = 6 for both non‐tumor and tumor tissues in AOM/DSS ^+^−ICG ^−^; n = 47 for non‐tumor tissues; n = 40 for tumor tissues in AOM/DSS ^+^−ICG ^+^; and n = 14 for normal tissues control (Cont)−ICG ^+^. Values represent mean + SD. \*\**P* \< .01 (Tukey‐Kramer\'s test or Steel‐Dwass test). (C) Tumor to normal tissue ratio of MFI of ICG in each time period: n = 24 for ICG ^−^; n = 15 for 4‐6 weeks; n = 23 for 10‐12 weeks; and n = 42 for 18‐20 weeks. Values represent mean + SD. \**P* \< .05; \*\**P* \< .01 (Tukey‐Kramer\'s test or Steel‐Dwass test)](CAS-109-1638-g001){#cas13564-fig-0001}

3.2. Changes in ICG fluorescence signal during tumor development {#cas13564-sec-0012}
----------------------------------------------------------------

Histologically, AOM/DSS‐treated mice developed multiple mucosal proliferative lesions of dysplasia, adenoma, and adenocarcinoma, all showing ICG fluorescence (Figure [2](#cas13564-fig-0002){ref-type="fig"}A,B). The macroscopic ICG fluorescence signal was significantly increased in the colon proliferative lesions compared with normal mucosa, accompanying significant signal increases in more advanced lesions (Figure [2](#cas13564-fig-0002){ref-type="fig"}C). The tumor to normal tissue ratio of ICG fluorescence was also significantly increased in more advanced lesions (Figure [2](#cas13564-fig-0002){ref-type="fig"}D). The ICG fluorescence data were applied to construct receiver operating characteristic curves as well as scatter plot to determine detection capability of mucosal proliferative lesions from dysplasia to adenocarcinoma in ICG fluorescence imaging (Figures [S2](#cas13564-sup-0001){ref-type="supplementary-material"} and [S3](#cas13564-sup-0001){ref-type="supplementary-material"}). As a result, the sensitivity/specificity for detection of the proliferative lesions was 87.1%/89.6% for proliferative lesions (cut‐off mean fluorescence intensity: 56.4 arbitrary units) and 63.8%/90.3% for differentiation of adenocarcinoma from adenoma (cut‐off mean fluorescence intensity, 143.6 arbitrary units), respectively.

![Ex vivo indocyanine green (ICG) fluorescence imaging of mouse colon tumor tissues during tumor development. Colon tissues of azoxymethane (AOM)/dextran sodium sulfate (DSS)‐treated mice with ICG injection were subjected to observation 1 h after i.v. injection of ICG at 4‐6, 10‐12, and 18‐20 weeks after AOM initiation. (A) Representative ICG fluorescence images of colon dysplasia (Dys), adenoma (Ad), and adenocarcinoma (Ca) tissues and corresponding H&E stained images (magnification, ×200). (B) Number of animals bearing each type of proliferative lesion in AOM/DSS‐treated mice that received i.v. injection of ICG with 1 h of circulation time in each time period. (C) Mean fluorescence intensity (MFI) of ICG in each type of tissue: n = 51 for normal tissues; n = 6 for Dys; n = 31 for Ad; and n = 48 for Ca. Values represent mean + SD. \**P* \< .05; \*\**P* \< .01 (Tukey‐Kramer\'s test or Steel‐Dwass test). (D) Tumor to normal tissue ratio of MFI of ICG in each type of proliferative lesion: n = 6 for Dys; n = 31 for Ad; and n = 48 for Ca. Values represent mean + SD. \*\**P* \< .01 (Tukey‐Kramer\'s test or Steel‐Dwass test)](CAS-109-1638-g002){#cas13564-fig-0002}

3.3. Microscopic analysis of ICG fluorescence localization in the colon tumor tissues {#cas13564-sec-0013}
-------------------------------------------------------------------------------------

Ex vivo microscopic imaging revealed that blood vessels in the tumor tissues showed distorted and thick vasculatures compared with normal mucosal blood vessels (Figure [3](#cas13564-fig-0003){ref-type="fig"}A). In the tumor tissues, ICG fluorescence was distributed in the stromal tissues around the blood vessels in each time period (Figure [3](#cas13564-fig-0003){ref-type="fig"}A, Figure [S1](#cas13564-sup-0001){ref-type="supplementary-material"}). The ICG fluorescence was unevenly distributed in the mucosa and not in the muscle layer (Figure [3](#cas13564-fig-0003){ref-type="fig"}A). Indocyanine green fluorescence was not observed in the tumor parenchyma in any time period (Figures [3](#cas13564-fig-0003){ref-type="fig"}A, Figures [S1](#cas13564-sup-0001){ref-type="supplementary-material"}). The tumor to normal tissue ratio of ICG fluorescence in mice 10‐12 or 18‐20 weeks after injection of AOM was significantly higher than that in the ICG non‐administered group (Figure [3](#cas13564-fig-0003){ref-type="fig"}B).

![Microscopic imaging of indocyanine green (ICG) fluorescence distribution in mouse colon tumor tissues. High‐power view of colon tissues in azoxymethane (AOM)/dextran sodium sulfate (DSS)‐treated mice with/without ICG injection was acquired 1 h after i.v. administration of ICG at 4‐6, 10‐12, and 18‐20 weeks after AOM initiation. (A) ICG fluorescence images (green) with *Lycopersicon esculentum* (tomato) lectin conjugated with DyLight 488 (TL488) fluorescence (red) staining blood vessels in AOM/DSS‐treated mice with ICG injection in the time period of 18‐20 weeks after AOM initiation. Arrowheads indicate the border of mucosal and muscle layers. (B) Tumor to normal tissue ratio of mean fluorescence intensity of ICG in high‐power view of colon tumor tissues. The data of AOM/DSS‐treated ICG non‐administered group were shown as a sum of mice obtained from each time period (n = 1 for 4‐6 weeks, n = 2 for 10‐12 weeks, and n = 1 for 18‐20 weeks). The sample number of tumor tissues was n = 6 for 4‐6 weeks, n = 14 for 10‐12 weeks, and n = 34 for 18‐20 weeks, respectively. Values represent mean + SD. \**P* \< .05 and \*\**P* \< .01 (Tukey‐Kramer\'s test or Steel‐Dwass test)](CAS-109-1638-g003){#cas13564-fig-0003}

3.4. Vascular component analysis in colon tumor tissues {#cas13564-sec-0014}
-------------------------------------------------------

The area of CD31^+^ endothelial cells in the tumor tissues was larger and thicker than that of normal colon tissues (Figure [4](#cas13564-fig-0004){ref-type="fig"}A). CD31^+^ endothelial cells covered with/without α‐smooth muscle actin‐positive pericytes were observed in both normal colon tissues from untreated mice or AOM/DSS‐treated mice and tumor tissues from AOM/DSS‐treated mice (Figure [4](#cas13564-fig-0004){ref-type="fig"}A). The CD31^+^ area in the tumor tissues was significantly increased compared with that of normal colon tissues from untreated mice or AOM/DSS‐treated mice (Figure [4](#cas13564-fig-0004){ref-type="fig"}B). The CD31^+^ area in normal colon tissues of AOM/DSS‐treated mice did not differ from that of untreated mice (Figure [4](#cas13564-fig-0004){ref-type="fig"}B).

![Immunofluorescence imaging of blood vessel components in the colon tumor tissues. Immunofluorescence of CD31 (green) and α‐smooth muscle actin (αSMA) (red) with nuclear staining (blue) was carried out using the colon tissue sections obtained from azoxymethane (AOM)/dextran sodium sulfate (DSS)‐treated mice or untreated mice at 18‐20 weeks after AOM initiation. (A) Immunofluorescence images of CD31 and αSMA. Immunofluorescence images as shown in the boxed areas indicate the field‐of‐view of the magnified images. Arrows indicate CD31^+^ endothelial cells. (B) Mean microvessel area showing CD31^+^ endothelial cell‐occupied area in the field‐of‐view (1.82 × 10^4^ μm^2^; n = 12 for normal tissues from non‐treated mice, n = 14 for non‐tumor tissues, and n = 36 for tumor tissues from AOM/DSS‐treated mice). Values represent mean + SD. \*\**P* \< .01 (Tukey‐Kramer\'s test or Steel‐Dwass test)](CAS-109-1638-g004){#cas13564-fig-0004}

3.5. Vascular permeability in colon tumor tissues {#cas13564-sec-0015}
-------------------------------------------------

Vascular permeability is known to be promoted by inflammatory mediators, such as COX‐2, iNOS, and HO‐1.[33](#cas13564-bib-0033){ref-type="ref"} Immunoreactivity of COX‐2 was observed in stromal cells in the colon tissues (Figure [5](#cas13564-fig-0005){ref-type="fig"}A). The COX‐2^+^ cells were distributed in the interstitium of lamina propria mucosa in normal colon tissues of untreated control mice or AOM/DSS‐treated mice. In the colon tumor tissues, COX‐2^+^ stromal cells were profoundly increased (Figure [5](#cas13564-fig-0005){ref-type="fig"}A). Immunoreactivity of HO‐1 was also observed in stromal cells in the colon tissues (Figure [S4](#cas13564-sup-0001){ref-type="supplementary-material"}). Although HO‐1^+^ stromal cells in the tumor tissues were not abundant compared with COX‐2^+^ stromal cells, HO‐1^+^ stromal cells were also increased in tumor tissues compared with normal colon tissues of untreated control mice or AOM/DSS‐treated mice (Figure [S4](#cas13564-sup-0001){ref-type="supplementary-material"}). Immunoreactivity of iNOS was also increased in tumor tissues, whereas it was rarely observed in normal colon tissues (Figure [5](#cas13564-fig-0005){ref-type="fig"}B). Most of the iNOS^+^ cells were found to be tumor cells at the tumor luminal surface. Endothelial cells did not express these inflammatory mediators (Figure [5](#cas13564-fig-0005){ref-type="fig"}A,B and Figure [S4](#cas13564-sup-0001){ref-type="supplementary-material"}).

![Immunofluorescence imaging of molecules related to vascular permeability in mouse colon tumor tissues and in vitro endothelial cell permeability assay. For immunofluorescence, colon tissues obtained from azoxymethane (AOM)/dextran sodium sulfate (DSS)‐treated mice or untreated mice at 18‐20 weeks after AOM initiation were used. (A) Immunofluorescence images of COX‐2 (red) and CD31 (green) with nuclear staining (blue). White arrow indicates the direction of luminal side of tumor tissues. Yellow arrows indicate COX‐2^+^ stromal cells. (B) Immunofluorescence images of inducible nitric oxide synthase (iNOS) (red) with blood vessel (*Lycopersicon esculentum* \[tomato\] lectin conjugated with DyLight \[TL488\], green) and nuclear (blue) staining. White arrow indicates the direction of luminal side of tumor tissues. Yellow arrows indicate iNOS ^+^ tumor cells. (C) Representative wide‐field images of indocyanine green (ICG) fluorescence 1 min after intradermal injection of vehicle (left ear; white arrowhead) or prostaglandin E~2~ (PGE ~2~) (right ear; yellow arrowhead). ICG fluorescence was also shown by fire‐lookup table (LUT). (D) Mean fluorescence intensity (MFI) in the wide‐field images of ICG fluorescence (n = 4). \*\**P* \< .01 (matched‐pair *t*‐test). (E) Representative high‐power images of ICG fluorescence 10‐12 min after intradermal injection of vehicle (left ear) or PGE ~2~ (right ear). (F) MFI in the high‐power images of ICG fluorescence (n = 4). \**P* \< .05 (matched‐pair *t*‐test)](CAS-109-1638-g005){#cas13564-fig-0005}

In the endothelial cell permeability assay using an HH cell monolayer (Document [S1](#cas13564-sup-0001){ref-type="supplementary-material"}), ICG passed through the membrane without the monolayer, whereas ICG reduced permeability through the non‐treated monolayer (Figure [S5](#cas13564-sup-0001){ref-type="supplementary-material"}). Treatment with LPS to the monolayer weakly but insignificantly increased endothelial permeation of ICG (Figure [S5](#cas13564-sup-0001){ref-type="supplementary-material"}). Endothelial permeation of ICG was also increased under PGE~2~ or H~2~O~2~ treatment conditions, but the difference was statistically insignificant when compared with no treatment condition (Figure [S5](#cas13564-sup-0001){ref-type="supplementary-material"}). In coculture experiments using a HUVEC monolayer with HT‐29 cells and THP‐1 cells (Document [S1](#cas13564-sup-0001){ref-type="supplementary-material"}), endothelial permeation of ICG was weakly but insignificantly increased in the condition of HUVEC with HT‐29 and THP‐1 cells in combination, LPS‐activated THP‐1 cells alone and LPS‐activated THP‐1 cells and HT‐29 cells in combination (Figure [S5](#cas13564-sup-0001){ref-type="supplementary-material"}).

In the in vivo vascular permeability assay, ICG fluorescence was significantly increased in the ear after intradermal injection of PGE~2~ compared with ears injected with PBS (Figure [5](#cas13564-fig-0005){ref-type="fig"}C‐F).

3.6. Expression of tight junction and transporter molecules in colon tumor tissues {#cas13564-sec-0016}
----------------------------------------------------------------------------------

The localization of occludin at the apical cell border was observed both in the tumor tissues of AOM/DSS‐treated mice and normal colon epithelium of untreated control mice or AOM/DSS‐treated mice, whereas immunoreactivity of occludin in the tumor cell cytoplasm was increased compared with the normal colon epithelium (Figure [6](#cas13564-fig-0006){ref-type="fig"}A). Zonula occludens‐1 was expressed at the apical cell border both in the normal tissues and tumor tissues. The immunoreactivity of zonula occludens‐1 in the tumor cells was not changed from normal colon epithelium (Figure [6](#cas13564-fig-0006){ref-type="fig"}A). Immunoreactivity of NTCP was observed at the cell surface membrane both in the tumor cells and normal colon epithelial cells (Figure [6](#cas13564-fig-0006){ref-type="fig"}B). In the ICG enema experiment using AOM/DSS‐treated mice, ICG did not accumulate in the tumor tissues (Figure [S6](#cas13564-sup-0001){ref-type="supplementary-material"}).

![Immunofluorescence imaging of tight junction and transporter molecules in mouse colon tumor tissues. Immunofluorescence was carried out using colon tissue sections obtained from azoxymethane (AOM)/dextran sodium sulfate (DSS)‐treated mice or untreated mice at 18‐20 weeks after AOM initiation. (A) Immunofluorescence images of occludin or zonula occludens‐1 (ZO‐1) (red) with nuclear staining (blue). White arrow indicates the direction of luminal side of tumor tissues. Yellow arrows indicate occludin^+^ or ZO‐1^+^ apical cell borders. (B) Immunofluorescence images of sodium‐taurocholate co‐transporting polypeptide (NTCP) (red) with nuclear staining (blue)](CAS-109-1638-g006){#cas13564-fig-0006}

4. DISCUSSION {#cas13564-sec-0017}
=============

We have previously reported the utility of i.v. administered ICG in tumor detection using a mouse xenograft tumor model of a human colon cancer cell line.[24](#cas13564-bib-0024){ref-type="ref"} Similar results were also obtained in metastatic lesions of clinical colorectal cancers, including their carcinomatosis,[17](#cas13564-bib-0017){ref-type="ref"}, [18](#cas13564-bib-0018){ref-type="ref"} metastatic lymph node,[19](#cas13564-bib-0019){ref-type="ref"} or metastatic liver tumors using ICG.[20](#cas13564-bib-0020){ref-type="ref"} However, there are no reports regarding the capability of ICG‐based tumor imaging in colitis‐associated colon cancer. The current animal model was created by 1 week of treatment with 5 w/v% DSS after AOM injection followed by a 4‐20‐week observation period. We further showed that ICG‐based tumor imaging can be achieved in slowly growing colon tumors developed in animals treated with 1 week of 2 w/v% DSS after AOM injection with a 61‐week observation period (Figure [S7](#cas13564-sup-0001){ref-type="supplementary-material"}). Thus, the present study is the first report in which i.v. administered ICG was used in the identification of colon tumor lesions of an AOM/DSS‐induced colitis‐associated colon cancer model. Furthermore, ICG fluorescence signal in the current model showed correlation with tumor malignancy. Judging from the data of the receiver operating characteristic analysis, this technique can be applied to diagnosis of colitis‐associated colon tumors.

Colon tumor tissues induced in the current animal model showed distorted and thick vasculature. Immunofluorescence microscopy analysis revealed that the CD31^+^ endothelial cell area in the tumor tissues was increased compared to the normal colon tissues. A previous study using several experimentally induced or spontaneously occurring tumors showing different angiogenesis capabilities reported that the fluorescence intensity of i.v. administered ICG correlates with microvascular density.[27](#cas13564-bib-0027){ref-type="ref"} These results suggested that ICG accumulation in the tumor tissues was likely promoted by increasing tumor vascularity, leading to an increase in the chance for ICG to extravasate from tumor blood vessels.

In the present study, ICG fluorescence was distributed in the stromal tissues around the tumor blood vessels, whereas only weak ICG fluorescence was observed in the normal colon stromal tissues. Therefore, it can be postulated that blood vessel permeability of ICG plays a major role in ICG accumulation in the tumor tissues. It is known that extravasation of i.v. administered agents from blood vessels is promoted by the absence of pericytes.[34](#cas13564-bib-0034){ref-type="ref"} However, in the present study, endothelial cells covered with/without α‐smooth muscle actin‐positive pericytes were observed in both normal colon tissues and colon tumor tissues. Therefore, these results suggest a minor role of the lack of pericyte coverage of endothelial cells in ICG‐mediated tumor enhancement in the current model. However, vascular permeability is also known to be promoted by inflammatory mediators, such as COX‐2, iNOS, and HO‐1.[33](#cas13564-bib-0033){ref-type="ref"} In our study, strong immunoreactivities of COX‐2, iNOS, and HO‐1 were observed in the AOM/DSS‐induced tumor colon tissues, similar to previous studies.[35](#cas13564-bib-0035){ref-type="ref"}, [36](#cas13564-bib-0036){ref-type="ref"} Furthermore, we showed that endothelial cell permeability of ICG in vitro was promoted by both PGE~2~, a downstream product of COX‐2,[33](#cas13564-bib-0033){ref-type="ref"} and H~2~O~2~, an upstream reactive oxygen species of iNOS.[33](#cas13564-bib-0033){ref-type="ref"}, [37](#cas13564-bib-0037){ref-type="ref"} Prostaglandin E~2~ is known to increase local blood flow, resulting in vascular hyperpermeability.[32](#cas13564-bib-0032){ref-type="ref"} In the present study, intradermal injection of PGE~2~ induced ICG permeability and accumulation in normal ear tissues, suggesting that enhanced permeability induced by PGE~2~ was likely to be one of the mechanisms of tumor accumulation of ICG. Taken together, these results suggest that preferential accumulation of ICG in the tumor tissues can be attributed to the increase of tumor vascular permeability involving inflammatory mediators, such as COX‐2 and iNOS, in conjunction with increasing tumor vasculature. In addition, accumulation capability of agents to the tumor tissues may be affected by impaired lymphatic drainage, which enhances agent retention in the tumor tissues, and enhanced vascular permeability, which promotes agent delivery to the tumor tissues.[38](#cas13564-bib-0038){ref-type="ref"} Therefore, future work will be needed to clarify the contribution of the retention effect on ICG‐based tumor imaging.

In the AOM/DSS‐induced tumor tissues in the present study, tumor cells did not take up ICG, whereas ICG was distributed in the stromal tissues around the tumor parenchyma. Furthermore, ICG did not accumulate in the tumor tissues, even in the ICG enema experiment, in contrast to ICG accumulation by ICG enema in AOM‐induced colon tumor tissues using rats in our previous study.[25](#cas13564-bib-0025){ref-type="ref"} In our previous study using a mouse xenograft model of human colon cancer cells, we revealed that cellular uptake of ICG is mediated by endocytosis in association with disruption of tight junctions.[24](#cas13564-bib-0024){ref-type="ref"} In another study using rats, as mentioned above, we also reported altered expression of occludin, which could lead to disruption of tight junctions and further endocytosis of ICG, in parallel with tumor cellular uptake of ICG.[25](#cas13564-bib-0025){ref-type="ref"} However, in the present study, immunolocalization of occludin in the tumor cells was observed at the apical cell border, similar to normal epithelial cells, suggesting the formation of functionally active tight junctions in tumor cells. These data suggest that tumor cells developed in the current model did not have ICG uptake capability because of low endocytic activity in conjunction with the formation of tight junctions.

In conclusion, our data indicated that fluorescence contrast‐enhanced imaging following i.v. administered ICG can be applied to the detection of colon tumors in a mouse colitis‐associated colon cancer model. The tumor tissue preference of ICG in the present model can be attributed to the enhanced vascular leakage of ICG in association with overexpression of inflammatory mediators, such as COX‐2 and iNOS, in conjunction with increased tumor vascularity. Our findings provide the justification for the choice of ICG‐based colon tumor imaging, irrespective of the tumor cell phenotype.
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